WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 581388
CAS#: 1187451-19-9
Description: Omidenepag isopropyl is a novel, selective, non-prostanoid EP2 receptor agonist. It can be used for treatment of open-angle glaucoma and ocular hypertension. Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag.[5] Omidenepag is a selective prostaglandin E2 receptor agonist. It was approved for medical use in Japan in 2018, and in the United States in September 2022.
MedKoo Cat#: 581388
Name: Omidenepag Isopropyl
CAS#: 1187451-19-9
Chemical Formula: C26H28N6O4S
Exact Mass: 520.1893
Molecular Weight: 520.61
Elemental Analysis: C, 59.98; H, 5.42; N, 16.14; O, 12.29; S, 6.16
Synonym: Omidenepag isopropyl; DE-117; DE 117; DE117
IUPAC/Chemical Name: Propan-2-yl N-(6-((N-((4-(1H-pyrazol-1-yl)phenyl)methyl)pyridine-3-sulfonamido)methyl)pyridin-2-yl)glycinate
InChi Key: VIQCWEGEHRBLAC-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H28N6O4S/c1-20(2)36-26(33)17-28-25-8-3-6-22(30-25)19-31(37(34,35)24-7-4-13-27-16-24)18-21-9-11-23(12-10-21)32-15-5-14-29-32/h3-16,20H,17-19H2,1-2H3,(H,28,30)
SMILES Code: O=C(OC(C)C)CNC1=NC(CN(CC2=CC=C(N3N=CC=C3)C=C2)S(=O)(C4=CC=CN=C4)=O)=CC=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 520.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Matsou A, Anastasopoulos E. Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma. Expert Opin Investig Drugs. 2018 Sep 19:1-9. doi: 10.1080/13543784.2018.1526279. [Epub ahead of print] PubMed PMID: 30227753.
2: Iwamura R, Tanaka M, Okanari E, Kirihara T, Odani-Kawabata N, Shams N, Yoneda K. Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl. J Med Chem. 2018 Aug 9;61(15):6869-6891. doi: 10.1021/acs.jmedchem.8b00808. Epub 2018 Jul 30. PubMed PMID: 29995405.
3: Fuwa M, Toris CB, Fan S, Taniguchi T, Ichikawa M, Odani-Kawabata N, Iwamura R, Yoneda K, Matsugi T, Shams NK, Zhang JZ. Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. J Ocul Pharmacol Ther. 2018 Sep;34(7):531-537. doi: 10.1089/jop.2017.0146. Epub 2018 Jul 10. PubMed PMID: 29989843.
4: Impagnatiello F, Bastia E, Almirante N, Brambilla S, Duquesroix B, Kothe AC, Bergamini MVW. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. Br J Pharmacol. 2018 Apr 18. doi: 10.1111/bph.14328. [Epub ahead of print] Review. PubMed PMID: 29669171.
5: Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, Shimazaki A, Matsugi T, Shams N, Zhang JZ. Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent. Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):145-153. doi: 10.1167/iovs.17-22745. PubMed PMID: 29332128.
